tradmap

UTMD Financials UTAH MEDICAL PRODUCTS INC

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has declined 1.8% per year over the past 5 years.
  • Net income has grown faster than revenue (0.9% vs -1.8% per year).
  • Operating margin has contracted, at 29.6% in the latest year.
  • Free cash flow has declined 5.8% per year over the past 5 years.

Financial health

  • The company holds more cash ($86M) than total debt ($0).

Shareholder returns

  • Dividends have been paid for 15 consecutive years, consuming 35.3% of earnings and 27.8% of free cash flow.
  • The dividend has declined 0.7% per year over the past 5 years.
Revenue & net income
$0 $26M $52M 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 32% 64% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $11M $22M 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $46M $93M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$27M -$2M $22M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $39M $11M 57.1% 29.6% $14M $0 $86M
2024 $41M $14M 59.0% 33.2% $15M $0 $83M
2023 $50M $17M 59.8% 33.4% $22M $0 $93M
2022 $52M $16M 61.6% 37.9% $20M $0 $75M
2021 $49M $15M 63.0% 38.5% $21M $0 $61M
2020 $42M $11M 60.6% 32.5% $19M $0 $52M
2019 $47M $15M 62.8% 37.6% $17M $0 $43M
2018 $42M $19M 62.6% 44.5% $16M $0 $51M
2017 $41M $9M 63.7% 45.9% $15M $0 $40M
2016 $39M $12M 60.3% 41.2% $11M — $26M
2015 — $12M — — $14M $1013 $23M
2014 — $11M — — $14M $5065 $19M
2013 — $11M — — $12M $9003 $14M
2012 — $10M — — $13M — $9M
2011 — $7M — — $11M — $7M

Valuation over time

How the market has priced UTMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 9.5 19.1 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 3.0 6.0 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S
Dividend yield (%)
0.0 1.3 2.6 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
Dividend yield %

Frequently asked questions

Is UTMD growing its revenue and profit?

Over the past 5 years, UTAH MEDICAL PRODUCTS INC's revenue has declined 1.8% per year, and net income grown 0.9% per year. These are computed facts, not advice.

How much debt does UTMD have?

As of FY2025, UTAH MEDICAL PRODUCTS INC reported $0 of total debt against $86M of cash.

What is UTMD's profit margin?

In FY2025, gross margin was 57.1%, operating margin 29.6%, and net margin 29.3%.

What is UTMD's P/E ratio?

As of Jun '26, UTAH MEDICAL PRODUCTS INC traded at a price-to-earnings ratio of about 18.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.